Asthma Clinical Trial
Official title:
A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX(R) 160/4.5 mcg Inhalation Powder Versus SYMBICORT(R) TURBOHALER(R) 200/6 mcg in Adult and Adolescent Patients With Persistent Asthma
Verified date | March 2023 |
Source | Teva Branded Pharmaceutical Products R&D, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of the study is to establish whether budesonide/formoterol fumarate dihydrate (BF) Spiromax 160/4.5 micrograms (mcg) is as effective as Symbicort Turbohaler 200/6 mcg administered twice daily in participants with persistent asthma.
Status | Completed |
Enrollment | 605 |
Est. completion date | March 20, 2014 |
Est. primary completion date | March 20, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Male or female participants 12 years and older as of the screening visit. Male or female participants 18 years and older, as of the screening visit, in countries where local regulations or the regulatory status of study medication permit enrollment of adult participants only. - General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the participant at increased risk during the study. - Asthma Diagnosis: The asthma diagnosis must be in accordance with the Global Initiative for Asthma (GINA) Exclusion Criteria: - History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures. - Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks before the screening visit. In addition, the participant must be excluded if such infection occurs between the screening visit and the baseline visit. - Any asthma exacerbation requiring oral corticosteroids within 1 month of the screening visit. A participant must not have been hospitalized for asthma within 6 months before the screening visit. - Presence of glaucoma, cataracts, ocular herpes simplex, or malignancy other than basal cell carcinoma. - Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular conditions (for example, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine conditions (for example, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal conditions (for example, poorly-controlled peptic ulcer, gastroesophageal reflux disease [GERD]), or pulmonary conditions (for example, chronic bronchitis, emphysema, bronchiectasis with the need for treatment, cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the participant at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition became exacerbated during the study. NOTE: Other inclusion and exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Austria | Teva Investigational Site 33020 | Grieskirchen | |
Austria | Teva Investigational Site 33019 | Linz | |
Austria | Teva Investigational Site 33018 | Wels | |
Belgium | Teva Investigational Site 37029 | Gozee | |
Belgium | Teva Investigational Site 37031 | Halen | |
Belgium | Teva Investigational Site 37030 | Jambes | |
Czechia | Teva Investigational Site 54056 | Brno | |
Czechia | Teva Investigational Site 54061 | Hradec Kralove | |
Czechia | Teva Investigational Site 54068 | Neratovice | |
Czechia | Teva Investigational Site 54063 | Ostrava - Marianske Hory | |
Czechia | Teva Investigational Site 54065 | Plzen | |
Czechia | Teva Investigational Site 54058 | Praha | |
Czechia | Teva Investigational Site 54067 | Praha | |
Czechia | Teva Investigational Site 54064 | Rokycany | |
Czechia | Teva Investigational Site 54059 | Strakonice | |
Denmark | Teva Investigational Site 39020 | Copenhagen NV | |
Denmark | Teva Investigational Site 39021 | Odense | |
Finland | Teva Investigational Site 40004 | Helsinki | |
Finland | Teva Investigational Site 40005 | Jyvaskyla | |
Finland | Teva Investigational Site 40002 | Pori | |
Finland | Teva Investigational Site 40001 | Tampere | |
Finland | Teva Investigational Site 40003 | Turku | |
France | Teva Investigational Site 35088 | Brest Cedex 2 | |
France | Teva Investigational Site 35089 | La Bouexiere | |
France | Teva Investigational Site 35093 | Lyon Cedex 04 | |
France | Teva Investigational Site 35092 | Murs Erigne | |
France | Teva Investigational Site 35090 | Nantes | |
France | Teva Investigational Site 35091 | Perpignan | |
Germany | Teva Investigational Site 32243 | Berlin | |
Germany | Teva Investigational Site 32255 | Berlin | |
Germany | Teva Investigational Site 32256 | Berlin | |
Germany | Teva Investigational Site 32257 | Berlin | |
Germany | Teva Investigational Site 32244 | Berlin-Neukolln | |
Germany | Teva Investigational Site 32252 | Cottbus | |
Germany | Teva Investigational Site 32251 | Frankfurt am Main | |
Germany | Teva Investigational Site 32253 | Frankfurt/Main | |
Germany | Teva Investigational Site 32254 | Gelsenkirchen | |
Germany | Teva Investigational Site 32259 | Grosshansdorf | |
Germany | Teva Investigational Site 32249 | Hamburg | |
Germany | Teva Investigational Site 32246 | Leipzig | |
Germany | Teva Investigational Site 32240 | Neu-Isenburg | |
Germany | Teva Investigational Site 32258 | Offenbach | |
Germany | Teva Investigational Site 32250 | Reinfeld | |
Germany | Teva Investigational Site 32241 | Rudersdorf | |
Germany | Teva Investigational Site 32247 | Weinheim | |
Hungary | Teva Investigational Site 51075 | Balassagyarmat | |
Hungary | Teva Investigational Site 51067 | Budapest | |
Hungary | Teva Investigational Site 51072 | Budapest | |
Hungary | Teva Investigational Site 51077 | Csorna | |
Hungary | Teva Investigational Site 51065 | Deszk | |
Hungary | Teva Investigational Site 51071 | Kaposvar | |
Hungary | Teva Investigational Site 51073 | Kaposvar | |
Hungary | Teva Investigational Site 51068 | Komarom | |
Hungary | Teva Investigational Site 51070 | Mosdos | |
Hungary | Teva Investigational Site 51076 | Tatabanya | |
Hungary | Teva Investigational Site 51074 | Torokbalint | |
Israel | Teva Investigational Site 80036 | Afula | |
Israel | Teva Investigational Site 80035 | Haifa | |
Israel | Teva Investigational Site 80040 | Kfar Saba | |
Israel | Teva Investigational Site 80039 | Petach Tikva | |
Israel | Teva Investigational Site 80037 | Ramat Gan | |
Israel | Teva Investigational Site 80038 | Rehovot | |
Israel | Teva Investigational Site 80041 | Zerifin | |
Italy | Teva Investigational Site 30055 | Cisanello Pisa | |
Italy | Teva Investigational Site 30056 | Milano | |
Italy | Teva Investigational Site 30054 | Padova | |
Netherlands | Teva Investigational Site 38048 | Alkmaar | |
Netherlands | Teva Investigational Site 38049 | Leeuwarden | |
Poland | Teva Investigational Site 53110 | Bialystok | |
Poland | Teva Investigational Site 53114 | Bialystok | |
Poland | Teva Investigational Site 53106 | Gdansk | |
Poland | Teva Investigational Site 53117 | Gdansk | |
Poland | Teva Investigational Site 53100 | Krakow | |
Poland | Teva Investigational Site 53109 | Krakow | |
Poland | Teva Investigational Site 53111 | Krakow | |
Poland | Teva Investigational Site 53107 | Lodz | |
Poland | Teva Investigational Site 53102 | Lublin | |
Poland | Teva Investigational Site 53116 | Poznan | |
Poland | Teva Investigational Site 53119 | Sopot | |
Poland | Teva Investigational Site 53103 | Strzelce Opolskie | |
Poland | Teva Investigational Site 53104 | Szczecin | |
Poland | Teva Investigational Site 53105 | Tarnow | |
Poland | Teva Investigational Site 53099 | Wroclaw | |
Poland | Teva Investigational Site 53115 | Wroclaw | |
Poland | Teva Investigational Site 53120 | Wroclaw | |
Poland | Teva Investigational Site 53113 | Zabrze | |
Poland | Teva Investigational Site 53101 | Zgierz | |
Russian Federation | Teva Investigational Site 50179 | Kazan | |
Russian Federation | Teva Investigational Site 50177 | Moscow | |
Russian Federation | Teva Investigational Site 50171 | Saint Petersburg | |
Russian Federation | Teva Investigational Site 50175 | Saint-Petersburg | |
Russian Federation | Teva Investigational Site 50172 | Saratov | |
Russian Federation | Teva Investigational Site 50178 | St. Petersburg | |
Russian Federation | Teva Investigational Site 50173 | Tomsk | |
Russian Federation | Teva Investigational Site 50170 | Vsevolozhsk | |
Russian Federation | Teva Investigational Site 50174 | Yaroslavl | |
Spain | Teva Investigational Site 31051 | Alcorcon | |
Spain | Teva Investigational Site 31054 | Badalona | |
Spain | Teva Investigational Site 31052 | Barcelona | |
Spain | Teva Investigational Site 31057 | Barcelona | |
Spain | Teva Investigational Site 31053 | Bilbao | |
Spain | Teva Investigational Site 31058 | Madrid | |
Spain | Teva Investigational Site 31056 | Pamplona | |
Spain | Teva Investigational Site 31055 | Sevilla | |
Spain | Teva Investigational Site 31061 | Vitoria | |
Sweden | Teva Investigational Site 42014 | Goteborg | |
Sweden | Teva Investigational Site 42011 | Lund | |
Sweden | Teva Investigational Site 42012 | Stockholm | |
United Kingdom | Teva Investigational Site 34024 | Chesterfield | |
United Kingdom | Teva Investigational Site 34026 | Coventry | |
United Kingdom | Teva Investigational Site 34022 | Dundee | |
United Kingdom | Teva Investigational Site 34027 | East Sussex | |
United Kingdom | Teva Investigational Site 34029 | Lancashire | |
United Kingdom | Teva Investigational Site 34028 | London |
Lead Sponsor | Collaborator |
---|---|
Teva Branded Pharmaceutical Products R&D, Inc. |
Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Weekly Average of Daily Trough (Predose and Pre-rescue Bronchodilator) Morning (AM) Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period | PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Baseline trough morning PEF was defined as the average value of recorded (nonmissing) morning assessments 5 out of the last 7 days prior to randomization. The first day before randomization consisted of the electronic patient diary entry at home on the morning of the randomization visit (Baseline [Day 1]) and the first day postrandomization consisted of the electronic patient diary entry at home on the morning of the day after the randomization visit (Baseline [Day 1]). For postdose weekly average of trough morning PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of morning PEF values divided by the number of nonmissing assessments. The final value for change from baseline was calculated as the average of the weekly change from baseline averaged over 12 weeks. | Baseline, Weeks 1 to 12 (averaged over 12 weeks) | |
Secondary | Change From Baseline in Weekly Average of Daily Evening (PM) PEF Over the 12-Week Treatment Period | PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Baseline was defined as the average value of the recorded (nonmissing) assessments over the 7 days prior to randomization. For postdose weekly average of evening PEF measurements, the values were the averages based on the available data for that week. The averages were calculated as the sum of evening PEF values divided by the number of nonmissing assessments. The final value for change from baseline was calculated as the average of the weekly change from baseline averaged over 12 weeks. | Baseline, Weeks 1 to 12 (averaged over 12 weeks) | |
Secondary | Number of Participants With Adverse Events (AEs) | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'. | Baseline up to Week 12 | |
Secondary | Number of Participants With Signs of Oral Candidiasis (Thrush) | Examinations were performed by a qualified professional. | Baseline, Week 4, Week 8, Week 12 | |
Secondary | Number of Participants With Positive Swab of Oral Candidiasis (Thrush) | Swab samples were collected by a qualified professional. | Baseline, Week 4, Week 8, Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|